Please assess the completion status of the following clinical trial:

Trial Title: A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* At least 18 years of age at screening~* HbA1c ≥ 8% and ≤ 12% at screening~* Fasting plasma glucose (FPG) ≤ 270 mg/dL (15mmol/L)~* Stable dose metformin ≥ 1500 mg per day with or without a stable dose of sulfonylurea (defined as at least 50% maximal dose per local label) for at least 8 weeks~* estimated glomerular filtration rate (eGFR) \&lt; 60 ml/ml/1.73m2~* Body Mass Index ≤ 45.0 kg/m2~Exclusion Criteria:~* Clinical diagnosis of Type 1 diabetes~* History of ketoacidosis~* Renal, hepatic or pancreatic disease~* Impairment of renal function (defined as creatinine clearance \[CrCl\] \< 60 mL/min~* Cardiovascular or vascular diseases identified within 3 months of participationImpairment of renal function (defined as creatinine clearance \[CrCl\] \< 60 mL/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin/Dapagliflozin/Metformin (Type: EXPERIMENTAL): Oral route. Saxagliptin/Dapa adminsitered once daily for 24 weeks at a dose of 5 mg Saxagliptin and 10 mg Dapagliflozin
- Insulin Glargine, Lantos/Metformin (Type: ACTIVE_COMPARATOR): Insulin glargine administered once a day with starting dose of 0.2 Unit per kg or 10 units.

Based on this trial design, predict the completion outcome and termination type (if applicable).